Literature DB >> 26580150

A New Empirical Definition of Major Depressive Episode Recovery and Its Positive Impact on Future Course of Illness.

Lewis L Judd1,2, Pamela J Schettler2, A John Rush3, William H Coryell4, Jess G Fiedorowicz4,5, David A Solomon6.   

Abstract

OBJECTIVE: To provide the first head-to-head test of the predictive validity of 2 resolution levels included in the current consensus definition of major depressive episode (MDE) recovery and provide an empirically based, clinically useful definition of the end of an MDE.
METHOD: 322 participants entering the National Institute of Mental Health Collaborative Depression Study with MDE (diagnosed by Research Diagnostic Criteria) in 1978-1981, and followed thereafter for up to 31 years, were divided into those with 8 consecutive weeks of asymptomatic MDE recovery or residual subsyndromal depressive symptom (SSD) resolution of their index MDE. These 2 levels of recovery were defined based on weekly symptom status on all depressive conditions, assessed by Longitudinal Interval Follow-Up Evaluation (LIFE) interviews conducted every 6 months. Primary measures of validity of these 2 alternative definitions were first well interval duration and long-term depressive illness burden. Groups were also compared on clinical variables, antidepressant treatment, and psychosocial function.
RESULTS: 61.2% of subjects recovered asymptomatically from their index MDE. By survival analysis, they remained free of a depressive episode relapse or recurrence 4.2 times longer than those with SSD resolution (median = 135 vs 32 weeks; χ² = 70.65; P < .0001). This was not attributable to a difference in intensity of antidepressant medication. Compared to asymptomatic recovery, SSD resolution was associated with significantly longer and more severe index MDEs, with more miscellaneous psychopathology as well as increased long-term psychosocial dysfunction and a greater depressive illness burden during the ensuing 10 or 20 years. Asymptomatic MDE resolution was a stronger predictor of time well than any of 18 other predictors, singly or combined. Eight consecutive weeks of asymptomatic recovery had 93% overlap with a 4-week definition and conferred little benefit over 4 weeks.
CONCLUSIONS: Four consecutive weeks of asymptomatic recovery defines the end of an MDE and the beginning of a stable well state with improved psychosocial function. Residual symptom resolution is a continuation of an active state of the episode, not the end of an MDE. © Copyright 2016 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Year:  2016        PMID: 26580150     DOI: 10.4088/JCP.15m09918

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  10 in total

1.  Targeting treatments for depression: what can our patients tell us?

Authors:  A John Rush
Journal:  Epidemiol Psychiatr Sci       Date:  2016-04-05       Impact factor: 6.892

2.  Follow-up of monotherapy remitters in the PReDICT study: Maintenance treatment outcomes and clinical predictors of recurrence.

Authors:  Jamie C Kennedy; Boadie W Dunlop; Linda W Craighead; Charles B Nemeroff; Helen S Mayberg; W Edward Craighead
Journal:  J Consult Clin Psychol       Date:  2018-02

3.  Applications of Yoga in Psychiatry: What We Know.

Authors:  Maren Nyer; Maya Nauphal; Regina Roberg; Chris Streeter
Journal:  Focus (Am Psychiatr Publ)       Date:  2018-01-24

4.  Thalamic Gamma Aminobutyric Acid Level Changes in Major Depressive Disorder After a 12-Week Iyengar Yoga and Coherent Breathing Intervention.

Authors:  Chris C Streeter; Patricia L Gerbarg; Richard P Brown; Tammy M Scott; Greylin H Nielsen; Liz Owen; Osamu Sakai; Jennifer T Sneider; Maren B Nyer; Marisa M Silveri
Journal:  J Altern Complement Med       Date:  2020-01-14       Impact factor: 2.579

5.  Evidence for Progressive Cognitive Deficits in Patients With Major Depressive Disorder.

Authors:  Jin Liu; Bangshan Liu; Mi Wang; Yumeng Ju; Qiangli Dong; Xiaowen Lu; Jinrong Sun; Liang Zhang; Hua Guo; Futao Zhao; Weihui Li; Li Zhang; Zexuan Li; Yan Zhang; Mei Liao; Lingjiang Li
Journal:  Front Psychiatry       Date:  2021-02-16       Impact factor: 4.157

6.  Impairments of Social Interaction in Depressive Disorder.

Authors:  Erhan Akinci; Max-Oskar Wieser; Simon Vanscheidt; Shirin Diop; Vera Flasbeck; Burhan Akinci; Cora Stiller; Georg Juckel; Paraskevi Mavrogiorgou
Journal:  Psychiatry Investig       Date:  2022-02-25       Impact factor: 2.505

7.  A randomised, double-blind, placebo-controlled study to evaluate the safety and efficacy of lamotrigine in the maintenance treatment of Chinese adult patients with bipolar I disorder.

Authors:  Ling Zhang; Honggeng Zhang; Lu-Xian Lv; Qingrong Tan; Xiufeng Xu; Jian Hu; Lu Zi; James Cooper; Abhay Phansalkar; Gang Wang
Journal:  Int J Bipolar Disord       Date:  2022-08-01

8.  Relapse prevention in adults with major depressive disorder treated with vilazodone: a randomized, double-blind, placebo-controlled trial.

Authors:  Suresh Durgam; Carl Gommoll; Raffaele Migliore; Changzheng Chen; Cheng-Tao Chang; Michelle Aguirre; Michael E Thase
Journal:  Int Clin Psychopharmacol       Date:  2018-11       Impact factor: 1.659

9.  Measurement of Symptom Change Following Web-Based Psychotherapy: Statistical Characteristics and Analytical Methods for Measuring and Interpreting Change.

Authors:  Eyal Karin; Blake F Dear; Gillian Z Heller; Milena Gandy; Nickolai Titov
Journal:  JMIR Ment Health       Date:  2018-07-12

10.  Empirical evidence for definitions of episode, remission, recovery, relapse and recurrence in depression: a systematic review.

Authors:  P L de Zwart; B F Jeronimus; P de Jonge
Journal:  Epidemiol Psychiatr Sci       Date:  2018-05-17       Impact factor: 6.892

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.